Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrr...

Cijeli opis

Bibliografski detalji

Glavni autori:	Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Zhiying Cindy Xu, Carmelo Carlo-Stella
Format:	Artigo
Jezik:	Inglês
Izdano:	Ferrata Storti Foundation 2023-08-01
Serija:	Haematologica
Online pristup:	https://haematologica.org/article/view/11243
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!